Prospective, Multi-Center, Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Gonadoliberin Agonist Lucrin Depot

Trial Profile

Prospective, Multi-Center, Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Gonadoliberin Agonist Lucrin Depot

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2013

At a glance

  • Drugs Leuprorelin (Primary) ; Leuprorelin (Primary)
  • Indications Endometriosis
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 12 Jun 2012 Actual patient number 401 added as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Feb 2012 Additional lead trial centre (Almedis) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top